Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies

Inclusion Criteria: 1. According to the diagnostic criteria of the Italian transplantation working group, patients with multiple myeloma or lymphoma diagnosed as "confirmed poor mobilization" or "predicted poor mobilization". 2. Patients with auto-HSCT indication. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0\~2. 4. Patients should be within age range of ≥18 and ≤75 years old. 5. Life expectancy ≥ 3 months. 6. Patients must be able to sign informed consent. Exclusion Criteria: 1. Patients with severe cardiac, hepatic or renal insufficiency, such as: * Cardiac function class II or higher or severe arrhythmia; * Serum direct bilirubin (DBIL)\>2× upper limit of normal (ULN); * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2× ULN; * Serum creatinine clearance rate≤50%. 2. Patients with active infection. 3. History of allergy to Etoposide (VP-16), Cytarabine (Ara-C), or PEG-rhG-CSF. 4. Women who are pregnant or breastfeeding. 5. Have received live vaccine and attenuated live vaccine within 4 weeks before enrollment. 6. For any other reasons, the patients are believed not suitable for participation in this study by investigators